A Phase 3 interventional study of Valsartan 160mg and Rosuvastatin 20mg in Hypertension, and Hyperlipidemia, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-15.
Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 72nd largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 53 in phase 3, and was the 122nd registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 168 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under LG Life Sciences, one of the names counted as LG Chem. Under that name alone:
LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
LG Chem has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
Drug: Valsartan 160mg · Drug: Rosuvastatin 20mg
Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Drug: Valsartan 160mg · Drug: Rosuvastatin 20mg placebo
Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
Drug: Rosuvastatin 20mg · Drug: Valsartan 160mg placebo
Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Drug: Valsartan 160mg placebo · Drug: Rosuvastatin 20mg placebo
Also known as: Diovan
Also known as: Crestor
sitDBP Changes at Week 8 From Baseline
sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline
Time frame: 8 weeks
LDL-C Percentage Changes at Week 8 From Baseline
LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline
Time frame: 8 weeks
| Milestone | Valsartan 160mg, Rosuvastatin 20mg | Valsartan 160mg, Rosuvastatin 20mg Placebo | Valsartan 160mg Placebo, Rosuvastatin 20mg | Placebo |
|---|---|---|---|---|
| Started | 43 | 41 | 39 | 45 |
| Completed | 35 | 36 | 30 | 38 |
| Not completed | 8 | 5 | 9 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 2 | 3 |
| Withdrew: Protocol violation | 6 | 2 | 6 | 3 |
| Withdrew: Lipid result by central lab did not meet | 0 | 0 | 1 | 0 |
sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline
| mmHg | V160+R20 & V160 | R20 & Placebo |
|---|---|---|
| sitDBP Changes at Week 8 From Baseline | -9.24 (-10.88 to -7.61) | -2.9 (-4.55 to -1.24) |
LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline
| percent change | V160+R20 & R20 | V160 & Placebo |
|---|---|---|
| LDL-C Percentage Changes at Week 8 From Baseline | -49.91 (-53.34 to -46.47) | -2.38 (-5.65 to 0.88) |
Collected over 12~14 weeks (4-6 weeks of Therapeutic Lifestyle Change + 8 weeks of Treatment period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan 160mg, Rosuvastatin 20mg | — | 1/43 (2.3%) | 10/43 (23.3%) |
| Valsartan 160mg, Rosuvastatin 20mg Placebo | — | 0/41 (0%) | 7/41 (17.1%) |
| Valsartan 160mg Placebo, Rosuvastatin 20mg | — | 0/37 (0%) | 4/37 (10.8%) |
| Placebo | — | 0/45 (0%) | 5/45 (11.1%) |
| Event | Valsartan 160mg, Rosuvastatin 20mg | Valsartan 160mg, Rosuvastatin 20mg Placebo | Valsartan 160mg Placebo, Rosuvastatin 20mg | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/43 | 0/41 | 0/37 | 0/45 |
| Event | Valsartan 160mg, Rosuvastatin 20mg | Valsartan 160mg, Rosuvastatin 20mg Placebo | Valsartan 160mg Placebo, Rosuvastatin 20mg | Placebo |
|---|---|---|---|---|
| headacheNervous system disorders | 2/43 | 0/41 | 0/37 | 3/45 |
| dyspepsiaGastrointestinal disorders | 1/43 | 2/41 | 0/37 | 0/45 |
| chest discomfortGeneral disorders | 0/43 | 2/41 | 0/37 | 0/45 |
| dizzinessNervous system disorders | 1/43 | 2/41 | 0/37 | 0/45 |
| nauseaGastrointestinal disorders | 2/43 | 0/41 | 0/37 | 0/45 |
| conjunctival haemorrhageEye disorders | 0/43 | 0/41 | 1/37 | 0/45 |
| astheniaGeneral disorders | 0/43 | 1/41 | 1/37 | 0/45 |
| chest painGeneral disorders | 0/43 | 0/41 | 1/37 | 0/45 |
| urinary tract infectionInfections and infestations | 0/43 | 0/41 | 1/37 | 0/45 |
| alanine aminotransferase increasedInvestigations | 1/43 | 0/41 | 1/37 | 1/45 |
Full Analysis Set
| Age, Categorical(Participants) | Valsartan 160mg, Rosuvastatin 20mg | Valsartan 160mg, Rosuvastatin 20mg Placebo | Valsartan 160mg Placebo, Rosuvastatin 20mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 24 | 21 | 29 | 100 |
| >=65 years | 15 | 16 | 14 | 15 | 60 |
| Sex: Female, Male(Participants) | Valsartan 160mg, Rosuvastatin 20mg | Valsartan 160mg, Rosuvastatin 20mg Placebo | Valsartan 160mg Placebo, Rosuvastatin 20mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 16 | 14 | 7 | 10 | 47 |
| Male | 25 | 26 | 28 | 34 | 113 |
The record gives a start of Apr 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Rosuvastatin